Lenalidomide Krka

Lenalidomide, the active ingredient in Lenalidomide Krka, is an immunomodulatory agent presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory support for global distribution.

Lenalidomide is used in hematologic malignancies and bone‑marrow failure disorders, targeting abnormal plasma cells and dysplastic clones.

- Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes: decreases transfusion dependence and modifies disease course in patients with lower‑risk MDS.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Rash: mild to moderate skin eruptions. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea: upset stomach often alleviated with food. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: blood clots requiring immediate medical attention. - Severe neutropenia: markedly low white blood cell count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

When prescribing Lenalidomide, clinicians should consider several safety and handling measures.

- Monitor blood counts: perform regular complete blood count assessments to detect cytopenias. - Assess renal function: adjust use in patients with impaired kidney function. - Evaluate thromboembolic risk: consider prophylactic anticoagulation in high‑risk individuals. - Counsel on teratogenic potential: enforce strict contraception for patients of child‑bearing potential. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Lenalidomide interacts with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may lower plasma concentrations of lenalidomide. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - Vaccines (live attenuated): reduced vaccine efficacy; avoid during treatment. - NSAIDs (e.g., ibuprofen): may increase risk of renal impairment.